PORTAL / USDT

PORTAL / TRY

RVN / BTC

PORTAL / BNB

PORTAL / FDUSD

CHESS / USDT

CHESS / USDC

PORTAL / BTC

VIC / USDT

DENT / ETH

PEOPLE / BTC

ROSE / BTC

BAKE / BTC

BAKE / TRY

JST / BTC

CHZ / BTC

OMNI / BTC

FIDA / BTC

BAKE / USDT

ARK / TRY

MAZDA LIMITED

PC JEWELLER LTD

SINDHU TRADE LINKS LTD

PARSVNATH DEVELOPER LTD

VERANDA LEARNING SOL LTD

J.G.CHEMICALS LIMITED

EIMCO ELECON (INDIA) LTD

ORIENT CERATECH LIMITED

EMAMI PAPER MILLS LIMITED

CAPITAL TRUST LTD

COOL CAPS INDUSTRIES LTD

REMUS PHARMACEUTICALS L

SHARDA MOTOR INDS LTD

IRIS CLOTHINGS LIMITED

PARAS DEF AND SPCE TECH L

CONTAINER CORP OF IND LTD

DREAMFOLKS SERVICES LTD

TRENT LTD

NUVAMA WEALTH MANAGE LTD

KRISHANA PHOSCHEM LIMITED

Click here to get full coverage on An Indian Drugmaker, Investigated by ProPublica Last Year, Has Recalled Two Dozen Medications Sold to U.S. Patients - ProPublica

An Indian Drugmaker, Investigated by ProPublica Last Year, Has Recalled Two Dozen Medications Sold to U.S. Patients  ProPublica

An Indian Drugmaker, Investigated by ProPublica Last Year, Has Recalled Two Dozen Medications Sold to U.S. Patients - ProPublica

Click here to get full coverage on Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) - PR Newswire

Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)  PR Newswire

Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) - PR Newswire

Click here to get full coverage on Glenmark gets five observations from USFDA for Monroe plant - The Economic Times

Glenmark gets five observations from USFDA for Monroe plant  The Economic Times

Glenmark gets five observations from USFDA for Monroe plant - The Economic Times

Click here to get full coverage on Glenmark launches olopatadine HCl 0.2% to US market - Eyes On Eyecare

Glenmark launches olopatadine HCl 0.2% to US market  Eyes On Eyecare

Glenmark launches olopatadine HCl 0.2% to US market - Eyes On Eyecare

Click here to get full coverage on AstraZeneca refused interim injunction on SPC for blockbuster diabetes treatment against Glenmark but swiftly obtains permission to appeal - A&O Shearman

AstraZeneca refused interim injunction on SPC for blockbuster diabetes treatment against Glenmark but swiftly obtains permission to appeal  A&O Shearman

AstraZeneca refused interim injunction on SPC for blockbuster diabetes treatment against Glenmark but swiftly obtains permission to appeal - A&O Shearman

Click here to get full coverage on Nearly 1.5 Million Bottles of Glenmark's ADHD Drug Atomoxetine Recalled - MedCentral

Nearly 1.5 Million Bottles of Glenmark's ADHD Drug Atomoxetine Recalled  MedCentral

Nearly 1.5 Million Bottles of Glenmark's ADHD Drug Atomoxetine Recalled - MedCentral

Click here to get full coverage on Nationwide Recall Hits Dozens of Common Generic Drugs—What You Need to Know - health.com

Nationwide Recall Hits Dozens of Common Generic Drugs—What You Need to Know  health.com

Nationwide Recall Hits Dozens of Common Generic Drugs—What You Need to Know - health.com

Click here to get full coverage on Glenmark issues another recall, this time for nearly 1.5M bottles of generic ADHD drug - Fierce Pharma

Glenmark issues another recall, this time for nearly 1.5M bottles of generic ADHD drug  Fierce Pharma

Glenmark issues another recall, this time for nearly 1.5M bottles of generic ADHD drug - Fierce Pharma

Click here to get full coverage on Divi's Labs, Max Healthcare, Glenmark Share Price Jumps to Yearly Highs; Strong Fundamentals Could Push Divi's Labs Higher - topnews.in

Divi's Labs, Max Healthcare, Glenmark Share Price Jumps to Yearly Highs; Strong Fundamentals Could Push Divi's Labs Higher  topnews.in

Divi's Labs, Max Healthcare, Glenmark Share Price Jumps to Yearly Highs; Strong Fundamentals Could Push Divi's Labs Higher - topnews.in

Click here to get full coverage on No damages for Glenmark in battle over Mundipharma’s Targin - JUVE Patent

No damages for Glenmark in battle over Mundipharma’s Targin  JUVE Patent

No damages for Glenmark in battle over Mundipharma’s Targin - JUVE Patent

Click here to get full coverage on The FDA Finally Visited an Indian Drug Factory Linked to U.S. Deaths. It Found Problems. - ProPublica

The FDA Finally Visited an Indian Drug Factory Linked to U.S. Deaths. It Found Problems.  ProPublica

The FDA Finally Visited an Indian Drug Factory Linked to U.S. Deaths. It Found Problems. - ProPublica

Click here to get full coverage on Glenmark Pharmaceuticals Inc., USA to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 - PR Newswire

Glenmark Pharmaceuticals Inc., USA to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30  PR Newswire

Glenmark Pharmaceuticals Inc., USA to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 - PR Newswire

Click here to get full coverage on Glenmark Pharmaceuticals Inc., USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials - PR Newswire

Glenmark Pharmaceuticals Inc., USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials  PR Newswire

Glenmark Pharmaceuticals Inc., USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials - PR Newswire

Click here to get full coverage on The FDA Hasn’t Inspected This Drug Factory After 7 Recalls for the Same Flaw, 1 Potentially Deadly - ProPublica

The FDA Hasn’t Inspected This Drug Factory After 7 Recalls for the Same Flaw, 1 Potentially Deadly  ProPublica

The FDA Hasn’t Inspected This Drug Factory After 7 Recalls for the Same Flaw, 1 Potentially Deadly - ProPublica

Click here to get full coverage on Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial - PR Newswire

Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial  PR Newswire

Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial - PR Newswire

Click here to get full coverage on Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) - PR Newswire

Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)  PR Newswire

Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) - PR Newswire

Click here to get full coverage on Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial) - PR Newswire

Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial)  PR Newswire

Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial) - PR Newswire

Click here to get full coverage on Glenmark Launches a Transformative Nutrition and Livelihood Project in Emali, Kenya - PR Newswire

Glenmark Launches a Transformative Nutrition and Livelihood Project in Emali, Kenya  PR Newswire

Glenmark Launches a Transformative Nutrition and Livelihood Project in Emali, Kenya - PR Newswire

Click here to get full coverage on Glenmark Therapeutics Inc., USA launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC) - PR Newswire

Glenmark Therapeutics Inc., USA launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC)  PR Newswire

Glenmark Therapeutics Inc., USA launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC) - PR Newswire

Click here to get full coverage on Glenmark Pharmaceuticals Inc., USA launches Clindamycin Phosphate Foam, 1% - PR Newswire

Glenmark Pharmaceuticals Inc., USA launches Clindamycin Phosphate Foam, 1%  PR Newswire

Glenmark Pharmaceuticals Inc., USA launches Clindamycin Phosphate Foam, 1% - PR Newswire

Click here to get full coverage on 100% of users reported hair growth in 12 weeks: Glenmark | 100% users saw hair growth by week 12: Glenmark | Inshorts - Inshorts

100% of users reported hair growth in 12 weeks: Glenmark | 100% users saw hair growth by week 12: Glenmark | Inshorts  Inshorts

100% of users reported hair growth in 12 weeks: Glenmark | 100% users saw hair growth by week 12: Glenmark | Inshorts - Inshorts

Click here to get full coverage on Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) - PR Newswire

Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL)  PR Newswire

Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) - PR Newswire

Click here to get full coverage on Trio of Indian drugmakers issue recalls tied to impurity, labeling issues - Fierce Pharma

Trio of Indian drugmakers issue recalls tied to impurity, labeling issues  Fierce Pharma

Trio of Indian drugmakers issue recalls tied to impurity, labeling issues - Fierce Pharma

Click here to get full coverage on HDFC Mutual Fund raises stake in Glenmark Pharmaceuticals to 5.07%. Details here - Mint

HDFC Mutual Fund raises stake in Glenmark Pharmaceuticals to 5.07%. Details here  Mint

HDFC Mutual Fund raises stake in Glenmark Pharmaceuticals to 5.07%. Details here - Mint

Click here to get full coverage on Glenmark to launch cancer drug Zanubrutinib in India - Mint

Glenmark to launch cancer drug Zanubrutinib in India  Mint

Glenmark to launch cancer drug Zanubrutinib in India - Mint

Click here to get full coverage on Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules - PR Newswire

Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules  PR Newswire

Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules - PR Newswire

Click here to get full coverage on Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast - GlobeNewswire

Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast  GlobeNewswire

Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast - GlobeNewswire

Click here to get full coverage on Glenmark Eyes Generic Flovent Launch In Coming Months Amid Expected US Resurgence - insights.citeline.com

Glenmark Eyes Generic Flovent Launch In Coming Months Amid Expected US Resurgence  insights.citeline.com

Glenmark Eyes Generic Flovent Launch In Coming Months Amid Expected US Resurgence - insights.citeline.com

Click here to get full coverage on Chartist Talks: Sudeep Shah of SBI Securities explains why he is bullish on these 6 stocks but flags... - Moneycontrol

Chartist Talks: Sudeep Shah of SBI Securities explains why he is bullish on these 6 stocks but flags...  Moneycontrol

Chartist Talks: Sudeep Shah of SBI Securities explains why he is bullish on these 6 stocks but flags... - Moneycontrol

Click here to get full coverage on UK Court of Appeal blocks Glenmark’s diabetes generic - JUVE Patent

UK Court of Appeal blocks Glenmark’s diabetes generic  JUVE Patent

UK Court of Appeal blocks Glenmark’s diabetes generic - JUVE Patent

Click here to get full coverage on Glenmark to launch DCGI-approved cancer drug in India - The Economic Times

Glenmark to launch DCGI-approved cancer drug in India  The Economic Times

Glenmark to launch DCGI-approved cancer drug in India - The Economic Times

Click here to get full coverage on Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting - GlobeNewswire

Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting  GlobeNewswire

Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting - GlobeNewswire

Click here to get full coverage on Glenmark recalls 15 lakh bottles of ADHD medication in US: USFDA - The Economic Times

Glenmark recalls 15 lakh bottles of ADHD medication in US: USFDA  The Economic Times

Glenmark recalls 15 lakh bottles of ADHD medication in US: USFDA - The Economic Times

Click here to get full coverage on Glenmark Adamant FDA Monroe Site Reinspection Could Happen ‘Any Time’ - insights.citeline.com

Glenmark Adamant FDA Monroe Site Reinspection Could Happen ‘Any Time’  insights.citeline.com

Glenmark Adamant FDA Monroe Site Reinspection Could Happen ‘Any Time’ - insights.citeline.com

Click here to get full coverage on Glenmark joins growing list of drugmakers to settle long-running US price-fixing claims - Fierce Pharma

Glenmark joins growing list of drugmakers to settle long-running US price-fixing claims  Fierce Pharma

Glenmark joins growing list of drugmakers to settle long-running US price-fixing claims - Fierce Pharma

Click here to get full coverage on Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreate - GlobeNewswire

Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreate  GlobeNewswire

Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreate - GlobeNewswire

Click here to get full coverage on 15 Lakh Bottles Of ADHD Medication Recalled In U.S. By Glenmark - NDTV

15 Lakh Bottles Of ADHD Medication Recalled In U.S. By Glenmark  NDTV

15 Lakh Bottles Of ADHD Medication Recalled In U.S. By Glenmark - NDTV

Click here to get full coverage on Glenmark Pharma Share Price Slumps After Q4 Results Miss Estimates - NDTV Profit

Glenmark Pharma Share Price Slumps After Q4 Results Miss Estimates  NDTV Profit

Glenmark Pharma Share Price Slumps After Q4 Results Miss Estimates - NDTV Profit

Click here to get full coverage on Glenmark Pharma's Monroe facility in North America gets five USFDA observations - CNBC TV18

Glenmark Pharma's Monroe facility in North America gets five USFDA observations  CNBC TV18

Glenmark Pharma's Monroe facility in North America gets five USFDA observations - CNBC TV18

Click here to get full coverage on Glenmark shares crash 6% after USFDA order discloses 39 drugs recalled from US market - Moneycontrol

Glenmark shares crash 6% after USFDA order discloses 39 drugs recalled from US market  Moneycontrol

Glenmark shares crash 6% after USFDA order discloses 39 drugs recalled from US market - Moneycontrol

Click here to get full coverage on Glenmark: USFDA Issues 5 Procedural Observations for Monroe Unit - Moneycontrol

Glenmark: USFDA Issues 5 Procedural Observations for Monroe Unit  Moneycontrol

Glenmark: USFDA Issues 5 Procedural Observations for Monroe Unit - Moneycontrol

Click here to get full coverage on Glenmark's cancer drug shows strong results in early trial for Myeloma - Business Standard

Glenmark's cancer drug shows strong results in early trial for Myeloma  Business Standard

Glenmark's cancer drug shows strong results in early trial for Myeloma - Business Standard

Click here to get full coverage on Glenmark Pharma rises 2% as company to launch blood cancer treatment drug - Business Standard

Glenmark Pharma rises 2% as company to launch blood cancer treatment drug  Business Standard

Glenmark Pharma rises 2% as company to launch blood cancer treatment drug - Business Standard

Click here to get full coverage on Glenmark’s myeloma drug delivers high response in phase-1 trial - Moneycontrol

Glenmark’s myeloma drug delivers high response in phase-1 trial  Moneycontrol

Glenmark’s myeloma drug delivers high response in phase-1 trial - Moneycontrol

Click here to get full coverage on Glenmark USA to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets - Business Standard

Glenmark USA to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets  Business Standard

Glenmark USA to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets - Business Standard

Click here to get full coverage on Glenmark’s technical breakout signals rally ahead: Religare’s Ajit Mishra - The Economic Times

Glenmark’s technical breakout signals rally ahead: Religare’s Ajit Mishra  The Economic Times

Glenmark’s technical breakout signals rally ahead: Religare’s Ajit Mishra - The Economic Times

Click here to get full coverage on Glenmark Pharma's US arm set to launch generic Adderall tablets - Business Standard

Glenmark Pharma's US arm set to launch generic Adderall tablets  Business Standard

Glenmark Pharma's US arm set to launch generic Adderall tablets - Business Standard

Click here to get full coverage on No revision, Glenmark Pharma sticking to full-year guidance: VS Mani - The Economic Times

No revision, Glenmark Pharma sticking to full-year guidance: VS Mani  The Economic Times

No revision, Glenmark Pharma sticking to full-year guidance: VS Mani - The Economic Times

Click here to get full coverage on Generic Drugs Recalled Due to Quality Issues - AARP

Generic Drugs Recalled Due to Quality Issues  AARP

Generic Drugs Recalled Due to Quality Issues - AARP

Click here to get full coverage on Glenmark-Ichnos cancer drug shows 74% response in phase-1 trial - Mint

Glenmark-Ichnos cancer drug shows 74% response in phase-1 trial  Mint

Glenmark-Ichnos cancer drug shows 74% response in phase-1 trial - Mint

Click here to get full coverage on Merck, Glenmark Lose Bid to Toss Claims in Zetia Antitrust Case - Bloomberg Law News

Merck, Glenmark Lose Bid to Toss Claims in Zetia Antitrust Case  Bloomberg Law News

Merck, Glenmark Lose Bid to Toss Claims in Zetia Antitrust Case - Bloomberg Law News

Click here to get full coverage on Glenmark, Sun Pharma, Zydus recall products in US over compliance issues - CNBC TV18

Glenmark, Sun Pharma, Zydus recall products in US over compliance issues  CNBC TV18

Glenmark, Sun Pharma, Zydus recall products in US over compliance issues - CNBC TV18

Click here to get full coverage on Glenmark to pay USD 7 mn to settle lawsuits with three entities in U.S. - The Hindu

Glenmark to pay USD 7 mn to settle lawsuits with three entities in U.S.  The Hindu

Glenmark to pay USD 7 mn to settle lawsuits with three entities in U.S. - The Hindu

Click here to get full coverage on Glenmark Pharmaceuticals Launches Pioneering Nutrition Program to Fight Malnutrition in the Philippines - PR Newswire

Glenmark Pharmaceuticals Launches Pioneering Nutrition Program to Fight Malnutrition in the Philippines  PR Newswire

Glenmark Pharmaceuticals Limited (GLENMARK)

Price Chart

Key Statistics

Technicals

About GLENMARK

Latest News

An Indian Drugmaker, Investigated by ProPublica Last Year, Has Recalled Two Dozen Medications Sold to U.S. Patients - ProPublica

Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) - PR Newswire

Glenmark gets five observations from USFDA for Monroe plant - The Economic Times

Advanced Charts

Top Gainers

Top Losers